Aerie pharmaceuticals to announce fourth quarter and full year 2019 financial results and host conference call on thursday, february 20, 2020
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2019 financial results will be released after the market closes on thursday, february 20, 2020. following the release, the company will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company’s financial results and provide a general business update. the live webcast and a replay may be accessed by visiting the company’s website at http://investors.aeriepharma.com. please connect to the company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call is 6595386. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call (855) 859-2056 (u.s.) or (404) 537-3406 (international). the conference id number for the replay is 6595386. the telephone replay will be available until february 28, 2020. about aerie pharmaceuticals, inc. aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. aerie’s first product, rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the u.s. food and drug administration (fda) for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension, was launched in the united states in april 2018. in clinical trials of rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. more information about rhopressa®, including the product label, is available at www.rhopressa.com. aerie’s second product for the reduction of elevated iop in patients with open-angle glaucoma or ocular hypertension, rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of rhopressa® and the widely-prescribed pga (prostaglandin analog) latanoprost, was approved by the fda and was launched in the united states in the second quarter of 2019. in clinical trials of rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. more information about rocklatan®, including the product label, is available at www.rocklatan.com. aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for dry eye, wet age-related macular degeneration and diabetic macular edema. more information is available at www.aeriepharma.com.
